246 related articles for article (PubMed ID: 21858223)
1. Aberrant activation of ERK/FOXM1 signaling cascade triggers the cell migration/invasion in ovarian cancer cells.
Lok GT; Chan DW; Liu VW; Hui WW; Leung TH; Yao KM; Ngan HY
PLoS One; 2011; 6(8):e23790. PubMed ID: 21858223
[TBL] [Abstract][Full Text] [Related]
2. Targeting GRB7/ERK/FOXM1 signaling pathway impairs aggressiveness of ovarian cancer cells.
Chan DW; Hui WW; Cai PC; Liu MX; Yung MM; Mak CS; Leung TH; Chan KK; Ngan HY
PLoS One; 2012; 7(12):e52578. PubMed ID: 23285101
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of FOXM1 is associated with metastases of nasopharyngeal carcinoma.
Jiang L; Wang P; Chen H
Ups J Med Sci; 2014 Nov; 119(4):324-32. PubMed ID: 25231007
[TBL] [Abstract][Full Text] [Related]
4. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system.
Huang C; Xie D; Cui J; Li Q; Gao Y; Xie K
Clin Cancer Res; 2014 Mar; 20(6):1477-88. PubMed ID: 24452790
[TBL] [Abstract][Full Text] [Related]
5. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression.
Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW
Mol Cancer Ther; 2008 Jul; 7(7):2022-32. PubMed ID: 18645012
[TBL] [Abstract][Full Text] [Related]
6. FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors.
Ahmad A; Wang Z; Kong D; Ali S; Li Y; Banerjee S; Ali R; Sarkar FH
Breast Cancer Res Treat; 2010 Jul; 122(2):337-46. PubMed ID: 19813088
[TBL] [Abstract][Full Text] [Related]
7. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
[TBL] [Abstract][Full Text] [Related]
8. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide expression analysis of Middle Eastern colorectal cancer reveals FOXM1 as a novel target for cancer therapy.
Uddin S; Ahmed M; Hussain A; Abubaker J; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Jehan Z; Bavi P; Siraj AK; Al-Kuraya KS
Am J Pathol; 2011 Feb; 178(2):537-47. PubMed ID: 21281787
[TBL] [Abstract][Full Text] [Related]
10. Differential functions of growth factor receptor-bound protein 7 (GRB7) and its variant GRB7v in ovarian carcinogenesis.
Wang Y; Chan DW; Liu VW; Chiu P; Ngan HY
Clin Cancer Res; 2010 May; 16(9):2529-39. PubMed ID: 20388850
[TBL] [Abstract][Full Text] [Related]
11. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.
Zhang X; Cheng L; Minn K; Madan R; Godwin AK; Shridhar V; Chien J
Oncotarget; 2014 Nov; 5(22):11365-80. PubMed ID: 25426548
[TBL] [Abstract][Full Text] [Related]
12. Down-regulation of FoxM1 by thiostrepton or small interfering RNA inhibits proliferation, transformation ability and angiogenesis, and induces apoptosis of nasopharyngeal carcinoma cells.
Jiang L; Wang P; Chen L; Chen H
Int J Clin Exp Pathol; 2014; 7(9):5450-60. PubMed ID: 25337187
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of FOXM1 predicts poor prognosis and promotes cancer cell proliferation, migration and invasion in epithelial ovarian cancer.
Wen N; Wang Y; Wen L; Zhao SH; Ai ZH; Wang Y; Wu B; Lu HX; Yang H; Liu WC; Li Y
J Transl Med; 2014 May; 12():134. PubMed ID: 24885308
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells.
Wang Z; Banerjee S; Kong D; Li Y; Sarkar FH
Cancer Res; 2007 Sep; 67(17):8293-300. PubMed ID: 17804744
[TBL] [Abstract][Full Text] [Related]
15. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer.
Kong X; Li L; Li Z; Le X; Huang C; Jia Z; Cui J; Huang S; Wang L; Xie K
Cancer Res; 2013 Jul; 73(13):3987-96. PubMed ID: 23598278
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of forkhead box protein M1 (FOXM1) in ovarian cancer correlates with poor patient survival and contributes to paclitaxel resistance.
Zhao F; Siu MK; Jiang L; Tam KF; Ngan HY; Le XF; Wong OG; Wong ES; Gomes AR; Bella L; Khongkow P; Lam EW; Cheung AN
PLoS One; 2014; 9(11):e113478. PubMed ID: 25411964
[TBL] [Abstract][Full Text] [Related]
17. FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma.
Ahmed M; Uddin S; Hussain AR; Alyan A; Jehan Z; Al-Dayel F; Al-Nuaim A; Al-Sobhi S; Amin T; Bavi P; Al-Kuraya KS
J Clin Endocrinol Metab; 2012 Jan; 97(1):E1-E13. PubMed ID: 22049175
[TBL] [Abstract][Full Text] [Related]
18. The critical role of dysregulated FOXM1-PLAUR signaling in human colon cancer progression and metastasis.
Li D; Wei P; Peng Z; Huang C; Tang H; Jia Z; Cui J; Le X; Huang S; Xie K
Clin Cancer Res; 2013 Jan; 19(1):62-72. PubMed ID: 23136192
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of FoxM1 offers a promising therapeutic target in diffuse large B-cell lymphoma.
Uddin S; Hussain AR; Ahmed M; Siddiqui K; Al-Dayel F; Bavi P; Al-Kuraya KS
Haematologica; 2012 Jul; 97(7):1092-100. PubMed ID: 22271891
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of FOXM1 by thiostrepton sensitizes medulloblastoma to the effects of chemotherapy.
Lin J; Zheng Y; Chen K; Huang Z; Wu X; Zhang N
Oncol Rep; 2013 Oct; 30(4):1739-44. PubMed ID: 23912794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
